[Contrast nephropathy and prevention]

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Context:

• Contrast-induced nephropathy (CIN) is a significant risk following radiocontrast procedures, particularly in patients with pre-existing renal impairment.
• Identifying effective preventative measures is crucial for managing high-risk patient populations.

Purpose:

• To explore the potential of trimetazidine (TMZ), a cytoprotective anti-ischemic agent, as a prophylactic treatment against contrast-induced nephropathy (CIN).
• To review current recommendations for CIN prevention, including hydration, bicarbonate, and N-acetylcysteine, and discuss adjunctive therapies.

Summary:

• Trimetazidine (TMZ) exhibits antioxidant and metabolic properties, influencing cellular and mitochondrial reperfusion, positioning it as a candidate for CIN prophylaxis.
• Standard preventive measures involve optimizing intravenous hydration, potentially with bicarbonate and N-acetylcysteine.
• In severe instances, hemofiltration may aid in contrast agent elimination, while urinary NGAL offers early detection of tubular damage.

Impact:

• This research highlights trimetazidine as a potential therapeutic agent to mitigate CIN risk.
• It emphasizes the importance of a multi-faceted approach to CIN prevention, combining established methods with novel pharmacological interventions.
• Early diagnostic markers like urinary NGAL could improve patient outcomes.